Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Once More Unto The Breach: 2014 NME Candidates Crowd In Familiar Fields

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With new drug candidates concentrated in already crowded markets like diabetes, antithrombotics and oncology, in 2014 sponsors must be prepared to demonstrate value not just to regulators but to payers as well. Merck, Lilly and AstraZeneca account for one-third of pending novel agents as the companies seek to recover from the patent cliff.

You may also be interested in...



PREVAIL Impresses, But Prostate Docs Wary Of Declaring Victory For Xtandi Over Zytiga

Bullish analysts predicted Xtandi easily wins over first-to-market Zytiga in pre-chemo prostate cancer, based on PREVAIL findings. But in the formal presentation at the ASCO GU meeting, clinicians were more reluctant to compare the two drugs and took a more nuanced interpretation of the data, given the important differences in study designs.

More Me-Too Drugs Please, FDA’s Jenkins Asks Industry

FDA’s top new drug official called out industry’s innovation model, noting that major primary care markets are being left underserved as sponsors focus on precision medicine and rare diseases.

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS005662

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel